News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Latest News
ASGCT: Cell & Gene Therapy Manufacturing Innovations Emerge
ASGCT Annual Meeting highlighted manufacturing innovations in cell and gene therapy production, addressing scalability, quality control, and supply chain challenges. Industry experts discussed process optimization, regulatory alignment, and collaborative strategies to accelerate CGT commercialization.
ASGCT: Manufacturing Innovations Take Center Stage
Manufacturing innovations dominated the ASGCT Annual Meeting, with industry leaders highlighting process optimization, automation, and regulatory compliance as critical drivers of scalable, cost-effective cell and gene therapy production.
THMA CPE Circle: Key Takeaways for Pharma Professionals
THMA CPE Circle delivers continuing pharmaceutical education and professional development for compliance, regulatory, and quality professionals. Key sessions address FDA regulations, digital transformation, and emerging industry trends shaping pharmaceutical operations.
ASGCT 2024: Gene Therapy Advancements Take Center Stage
ASGCT 2024 convened researchers and industry professionals to present advances in gene therapy and cell therapy. Specific clinical trial data and product announcements were not available in public sources at publication time; readers should consult official ASGCT abstracts and clinical trial registries for detailed conference coverage.
THMA Oncology Forum: Key Highlights and Emerging Trends
The THMA Oncology Forum represents a significant industry gathering for cancer research and treatment innovation. NovaPharmaNews will provide comprehensive coverage of novel therapies, clinical trials, and personalized medicine advances once official conference materials are publicly released.
FDLI 2026: Top Regulatory Insights & Policy Shifts
The 2026 FDLI Annual Conference highlighted critical shifts in pharmaceutical regulations, including FDA priorities for real-world evidence integration, post-market surveillance enhancement, and modernized approval pathways for complex therapeutics. Industry leaders discussed strategies for maintaining regulatory compliance while accelerating innovation.
APHL 2026: Key Highlights and Innovations in Public Health
APHL 2026 convened public health laboratory professionals to advance diagnostic testing, data analytics, and emergency preparedness. The conference highlighted innovations in laboratory science and the critical role of public health laboratories in protecting population health.
FDLI Annual 2026: Key Regulatory Insights & Policy Updates
The 2026 FDLI Annual Conference brought together pharmaceutical industry leaders and FDA officials to address evolving regulatory compliance challenges, including AI integration in drug development, supply chain security, and post-market surveillance strategies.
APHL 2026 Annual: Day 1 Key Takeaways
The APHL 2026 Annual Conference opened with focus on modernizing public health laboratory infrastructure, strengthening infectious disease surveillance, and addressing workforce challenges. Day 1 sessions highlighted diagnostic innovation, antimicrobial resistance surveillance, and quality assurance standards.
APHL 2026 Annual: Day 1 Highlights & Key Takeaways
The APHL 2026 Annual Conference convenes U.S. public health laboratory professionals to discuss advances in laboratory science, infectious disease surveillance, and diagnostic technologies. Day 1 programming focuses on laboratory operations, quality assurance, and emerging diagnostic innovations.
THMA Oncology Forum: Key Insights and Discussions
The THMA Oncology Forum convenes oncology professionals to discuss advances in cancer treatment, clinical trial outcomes, and emerging therapeutic strategies. While specific presentation details remain limited in public disclosures, the forum represents ongoing dialogue on personalized medicine, novel therapies, and collaborative initiatives shaping modern oncology.
IPEC Annual Meeting: Key Highlights and Industry Insights
The IPEC Annual Meeting is a premier pharmaceutical industry conference addressing excipient standards, regulatory compliance, and supply chain resilience. Current status of the 2026 pharmaceutical event requires official confirmation from the International Pharmaceutical Excipients Council.
FDLI Annual 2026: Key Regulatory Updates and Industry Trends
The FDLI Annual 2026 Conference convened industry leaders to address evolving pharmaceutical regulations, regulatory compliance challenges, and emerging trends in drug development, including AI integration, personalized medicine, and supply chain security.
THMA Oncology Forum: Key Insights and Discussions Day 1
The THMA Oncology Forum convenes oncology professionals to discuss advances in cancer treatment and clinical trials. Detailed Day 1 presentations and data require access to official conference materials and primary sources.
FDLI Annual 2026: Key Regulatory Insights & Policy Updates
The 2026 FDLI Annual Conference highlighted evolving pharmaceutical regulations, FDA priorities on accelerated review programs, and emerging challenges in AI-driven drug development. Industry leaders discussed regulatory compliance strategies, supply chain security, and real-world evidence integration.
THMA Oncology Forum: Key Insights and Discussions Day 1
The THMA Oncology Forum convenes oncology professionals and researchers to discuss advances in cancer treatment. Comprehensive coverage of Day 1 proceedings will be published upon release of official conference abstracts and materials.
FDLI Annual 2026: Key Regulatory Updates & Industry Insights
The 2026 FDLI Annual Conference brought together pharmaceutical industry leaders and FDA officials to discuss critical regulatory updates, including AI integration in drug development, supply chain security measures, and modernized pharmaceutical regulations designed to accelerate innovation while maintaining safety standards.
Palvella Therapeutics Begins Phase 2 Trial of QTORIN Rapamycin for Rare Angiokeratomas
Palvella Therapeutics doses first patients in Phase 2 LOTU trial of QTORIN rapamycin for angiokeratomas, targeting over 50,000 US patients with no approved treatments.
Neurocrine Biosciences Begins Phase 1 Trial of NBIP-2118 for Obesity Treatment
Neurocrine Biosciences initiates first-in-human Phase 1 trial for NBIP-2118, a novel CRF2 receptor agonist targeting obesity through non-incretin mechanisms.
CAPLYTA (Lumateperone) Ranks Highest Among FDA-Approved Adjunctive Depression Treatments in Network Meta-Analysis
New network meta-analysis shows CAPLYTA demonstrated superior efficacy across four key measures compared to other FDA-approved adjunctive MDD therapies.